These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32401814)

  • 21. Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.
    Hohenadl C; Wodal W; Kerschbaum A; Fritz R; Howard MK; Farcet MR; Portsmouth D; McVey JK; Baker DA; Ehrlich HJ; Barrett PN; Kreil TR
    Virol J; 2014 Apr; 11():70. PubMed ID: 24739285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Formation of antibodies against neuraminidase of A/California/07/2009 (H1N1) influenza virus after immunization with live monovalent influenza vaccine].
    Smolonogina TA; Desheva IuA; Shaldzhian AA; Grudinin MP; Rudenko LG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (6):72-6. PubMed ID: 22308734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections.
    Karunarathna HMTK; Perera RAPM; Fang VJ; Yen HL; Cowling BJ; Peiris M
    Emerg Microbes Infect; 2019; 8(1):404-412. PubMed ID: 30898033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine.
    Nayak JL; Fitzgerald TF; Richards KA; Yang H; Treanor JJ; Sant AJ
    J Infect Dis; 2013 Jan; 207(2):297-305. PubMed ID: 23148285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
    Sambhara V
    J Infect Dis; 2011 Jun; 203(11):1697-8. PubMed ID: 21593002
    [No Abstract]   [Full Text] [Related]  

  • 26. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach.
    Wagner R; Göpfert C; Hammann J; Neumann B; Wood J; Newman R; Wallis C; Alex N; Pfleiderer M
    Vaccine; 2012 Jun; 30(27):4113-22. PubMed ID: 22446639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.
    Uno S; Kimachi K; Matsuo F; Miyazaki K; Oohama A; Kei J; Nishimura T; Odoh K; Kino Y
    Microbiol Immunol; 2012 Dec; 56(12):810-6. PubMed ID: 23009167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.
    Berglund A; Willén L; Grödeberg L; Skattum L; Hagberg H; Pauksens K
    Acta Oncol; 2014 Sep; 53(9):1212-20. PubMed ID: 24865118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers.
    Yamane N; Nakamura Y; Yuki M; Odagiri T; Ishida N
    J Hyg (Lond); 1984 Apr; 92(2):231-42. PubMed ID: 6707472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
    Marcelin G; DuBois R; Rubrum A; Russell CJ; McElhaney JE; Webby RJ
    PLoS One; 2011; 6(10):e26335. PubMed ID: 22039464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain.
    Cortina-Ceballos B; Godoy-Lozano EE; Téllez-Sosa J; Ovilla-Muñoz M; Sámano-Sánchez H; Aguilar-Salgado A; Gómez-Barreto RE; Valdovinos-Torres H; López-Martínez I; Aparicio-Antonio R; Rodríguez MH; Martínez-Barnetche J
    Genome Med; 2015 Nov; 7():124. PubMed ID: 26608341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.
    Chan KH; To KK; Hung IF; Zhang AJ; Chan JF; Cheng VC; Tse H; Che XY; Chen H; Yuen KY
    Clin Vaccine Immunol; 2011 May; 18(5):867-73. PubMed ID: 21411604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
    Memoli MJ; Shaw PA; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Fargis S; Risos K; Powers JH; Davey RT; Taubenberger JK
    mBio; 2016 Apr; 7(2):e00417-16. PubMed ID: 27094330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.
    Carraro G; Naso A; Montomoli E; Gasparini R; Camerini R; Panatto D; Tineo MC; De Giorgi L; Piccirella S; Khadang B; Ceracchi M; De Rosa A
    Vaccine; 2012 Feb; 30(6):1170-80. PubMed ID: 22178096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
    Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.